Molecular diagnostics in HLA-incompatible kidney transplantation
Transplantation Reviews · 2026
DOI: 10.1016/j.trre.2026.101006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplantation Reviews, 2026. Verfasst von Miray Guney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Pragu…. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, HLA Antigens, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: European Rare Kidney Disease Reference Network, Ministry of Health of the Czech Republic, European Commission.
Abstract (Originalsprache)
Human leukocyte antigen-incompatible (HLA-i) kidney transplantation enables access to transplantation for highly sensitized patients with preformed donor-specific antibodies (DSA) but remains associated with frequent early DSA rebound and alloimmune endothelial injury, resulting in a high incidence of antibody-mediated rejection (AMR) despite current desensitization and induction protocols that include imlifidase. Kidney allograft biopsy remains the diagnostic gold standard for detecting overt and subclinical AMR, yet conventional histology does not always capture early or subclinical antibody-mediated injury, particularly in sensitized recipients. Tissue-based transcriptomics, Molecular Microscope Diagnostic system (MMDx) and Banff Human Organ Transplant gene panel (B-HOT), provide enhanced sensitivity for detecting molecular AMR phenotypes that often precede morphologic changes and may be particularly informative in the early post-transplant period. Plasma donor-derived cell-free DNA (dd-cfDNA) as non-invasive biomarker correlates with molecular rejection activity and may support longitudinal monitoring in sensitized high-risk patients, although interpretation is limited in the immediate post-transplant period. The integration of histology, DSA monitoring, transcriptomics, and emerging biomarkers enables a multimodal approach to AMR phenotyping, which is particularly critical in HLA-i transplantation to detect subclinical injury early, guide timely intervention, and prevent the development of chronic and largely untreatable transplant glomerulopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: miray.guney@ikem.cz.
- Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: petra.hruba@ikem.cz.
- Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Nephrology, Institute for Clinical an…
Förderung
- European Rare Kidney Disease Reference Network
- Ministry of Health of the Czech Republic
- European Commission
Zitieren
APA
Guney, M., Hruba, P., & Viklicky, O. (2026). Molecular diagnostics in HLA-incompatible kidney transplantation. Transplantation Reviews. https://doi.org/10.1016/j.trre.2026.101006
Vancouver
Guney M, Hruba P, Viklicky O. Molecular diagnostics in HLA-incompatible kidney transplantation. Transplantation Reviews. 2026. doi:10.1016/j.trre.2026.101006
BibTeX
@article{Guney2026,
author = {Guney, Miray and Hruba, Petra and Viklicky, Ondrej},
title = {Molecular diagnostics in HLA-incompatible kidney transplantation},
journal = {Transplantation Reviews},
year = {2026},
doi = {10.1016/j.trre.2026.101006}
}
EUVIMED